A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network

A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network

Abstract Background In the ongoing COVID-19 pandemic, advanced age is a risk factor for a severe clinical course of SARS-CoV-2 infection. Thus, older people may benefit in particular from booster doses with potent vaccines and research should focus on optimal vaccination schedules. In addition to ea...

Full description

Bibliographic Details
Main Authors: Julia M. Neuhann, Jannik Stemler, Antonio Carcas, Jesús Frías-Iniesta, Ullrich Bethe, Sarah Heringer, Lea Tischmann, Marouan Zarrouk, Arnd Cüppers, Franz König, Martin Posch, Oliver A. Cornely
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Trials
Subjects:
SARS-CoV-2
COVID-19 vaccination
BNT162b2 (Comirnaty®)
mRNA-1273 (Spikevax®)
Phase II
Randomisation
Online Access:https://doi.org/10.1186/s13063-022-06791-y

Internet

https://doi.org/10.1186/s13063-022-06791-y

Similar Items